Altered expression of STAT-3 deriving from polymorphic variants may predispose patients administered irinotecan-based chemotherapy to gastrointestinal (GI) epithelium damage and consequent side effects (i.e., mucositis, diarrhea). Here, STAT3 is linked to mucositis.